DiscoverCME in Minutes: Education in Primary CareCaron Jacobson, MD - Where Do Antibody–Drug Conjugates Fit in Relapsed/Refractory Diffuse Large B-Cell Lymphoma? Addressing Community Questions and Real-World Approaches to Selecting and Sequencing Novel Therapies
Caron Jacobson, MD - Where Do Antibody–Drug Conjugates Fit in Relapsed/Refractory Diffuse Large B-Cell Lymphoma? Addressing Community Questions and Real-World Approaches to Selecting and Sequencing Novel Therapies

Caron Jacobson, MD - Where Do Antibody–Drug Conjugates Fit in Relapsed/Refractory Diffuse Large B-Cell Lymphoma? Addressing Community Questions and Real-World Approaches to Selecting and Sequencing Novel Therapies

Update: 2025-11-25
Share

Description

Please visit answersincme.com/CAZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology-oncology answers the most commonly asked questions from clinicians about the management of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) with antibody–drug conjugates (ADCs). Upon completion of this activity, participants should be better able to: Identify patients with R/R DLBCL who may benefit from ADC therapy in the third-line or later setting; Interpret current evidence to inform selection of ADC therapies for patients with R/R DLBCL in the third-line or later setting; and Discuss strategies to optimize the use of ADC therapies for patients with R/R DLBCL, particularly in the community setting.
Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Caron Jacobson, MD - Where Do Antibody–Drug Conjugates Fit in Relapsed/Refractory Diffuse Large B-Cell Lymphoma? Addressing Community Questions and Real-World Approaches to Selecting and Sequencing Novel Therapies

Caron Jacobson, MD - Where Do Antibody–Drug Conjugates Fit in Relapsed/Refractory Diffuse Large B-Cell Lymphoma? Addressing Community Questions and Real-World Approaches to Selecting and Sequencing Novel Therapies

Answers in CME